Sponsor · clinical trials

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Italy, Belgium, Austria, Germany, Spain, Switzerland, UK, Netherlands, France, Sweden, Denmark, Norway and Portugal registers with Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company as lead sponsor. Synced 14 Nov 2026

4Current trials

1Recruiting now

5Drugs in these trials

13Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 14 Nov 2026 · Editorial standards

At a glance

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company is the lead sponsor of 4 current clinical trials in our Italy, Belgium, Austria, Germany, Spain, Switzerland, UK, Netherlands, France, Sweden, Denmark, Norway and Portugal registers. 1 is recruiting patients now. All registered phases are Observational. The drugs named most often in its trials are Bempedoic acid, Trastuzumab deruxtecan and Atorvastatin. The most-studied condition is Mixed Dyslipidemia.

ClinicalTrials.gov trials by status

Recruiting125%
Active, closed375%

Trials by phase

Observational4100%

Clinical trials sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

4 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
DESTINY Breast Respond HER2-(Ultra)Low Europe NCT05945732 · ClinicalTrials.gov ↗ · Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer Drug: Trastuzumab deruxtecan	Observational	Recruiting	2023-10	France, Spain, Italy, Belgium, Sweden, Denmark, Switzerland, Austria, Norway, Portugal
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia NCT06686615 · ClinicalTrials.gov ↗ · Primary Hypercholesterolemiia, Mixed Dyslipidemia Drugs: Atorvastatin, Bempedoic acid, Ezetimibe	Observational	Active, closed	2025-02	Germany, Spain, Italy, Belgium, Austria
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia NCT04579367 · Hypercholesterolemia, Mixed Dyslipidemia Drug: Bempedoic acid	Observational	Active, closed	2021-01	UK, Germany, Spain, Italy, Netherlands, Belgium, Switzerland, Austria
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) NCT05993234 · ClinicalTrials.gov ↗ · HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Drug: Trastuzumab deruxtecan	Observational	Active, closed	2023-12	Germany, Italy, Belgium, Austria

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Bempedoic acid2 Trastuzumab deruxtecan2 Atorvastatin1 Ezetimibe1 Rosuvastatin1

Conditions in Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company trials

9 conditions

Mixed Dyslipidemia2Hypercholesterolemia1Primary Hypercholesterolemiia1HER2-positive Advanced Gastric Cancer1HER2-positive Gastroesophageal Junction Adenocarcinoma1Unresectable Breast Cancer1Metastatic Breast Cancer1HER2-low Expressing Breast Cancer1HER2-(Ultra)Low Expressing Breast Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in Italy	4	1
Clinical trials in Belgium	4	1
Clinical trials in Austria	4	1
Clinical trials in Germany	3	0
Clinical trials in Spain	3	1
Clinical trials in Switzerland	2	1
Clinical trials in UK	1	0
Clinical trials in Netherlands	1	0
Clinical trials in France	1	1
Clinical trials in Sweden	1	1
Clinical trials in Denmark	1	1
Clinical trials in Norway	1	1
Clinical trials in Portugal	1	1

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Mixed Dyslipidemia

Sponsor	Trials
Addpharma	4
Shanghai Argo Biopharmaceutical	1

Sponsors with the most current trials registered for this condition.

Questions about Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company trials

How many clinical trials does Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company sponsor?

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company is the lead sponsor of 4 current trials on ClinicalTrials.gov in our Italy, Belgium, Austria, Germany, Spain, Switzerland, UK, Netherlands, France, Sweden, Denmark, Norway and Portugal registers, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.

Are Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company trials recruiting?

Yes. 1 of its 4 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Bempedoic acid (2), Trastuzumab deruxtecan (2), Atorvastatin (1), Ezetimibe (1) and Rosuvastatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.